Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Gonadorelin vs Histrelin (Supprelin LA / Vantas)
An educational, source-based comparison of Gonadorelin and Histrelin (Supprelin LA / Vantas) — how each peptide works, what it's researched for, and what to know before going deeper.
A synthetic decapeptide identical to endogenous gonadotropin-releasing hormone (GnRH). Pulsatile administration stimulates the anterior pituitary to release LH and FSH, supporting endogenous testosterone production and testicular size.
- HPG axis support during/after TRT
- Hypogonadotropic hypogonadism diagnosis
- Fertility-preservation protocols
- • Requires physician oversight, especially alongside TRT.
- • Continuous (non-pulsatile) administration suppresses the axis instead of stimulating it.
GnRH agonist implant for central precocious puberty and prostate cancer.
Synthetic nonapeptide GnRH agonist delivered via a subcutaneous hydrogel implant providing continuous release for 12 months, desensitizing the pituitary and suppressing sex steroids.
- Central precocious puberty (Supprelin LA)
- Advanced prostate cancer (Vantas)
- • FDA-approved.
- • Implant site reactions and rare implant breakage at removal.
Trial-evidence rating
Educational grade reflecting how many peer-reviewed studies and FDA actions we cite for each peptide. Not a clinical recommendation.
Early-stage research; conclusions are tentative.
FDA-approved with published clinical trial data.
Study-by-study comparison
| Peptide | Study | Source | Year | Summary |
|---|---|---|---|---|
| Gonadorelin | Pulsatile GnRH in hypogonadotropic hypogonadism | Journal of Clinical Endocrinology & Metabolism | 1997 | Restored LH/FSH and fertility in select hypogonadal men. |
| Histrelin (Supprelin LA / Vantas) | Histrelin implant in CPP | JCEM | 2007 | Sustained suppression of pubertal progression with single annual implant. |
Side-effect & safety grid
- Requires physician oversight, especially alongside TRT.
- Continuous (non-pulsatile) administration suppresses the axis instead of stimulating it.
- FDA-approved.
- Implant site reactions and rare implant breakage at removal.
Educational summary of considerations reported in research literature — not a complete list of adverse events. Discuss with a licensed clinician before any use.
Gonadorelin vs Histrelin (Supprelin LA / Vantas) — Key differences
- Class: Gonadorelin is classified as Hormonal · HPG Axis, while Histrelin (Supprelin LA / Vantas) is GnRH Agonist · Endocrine.
- Primary research focus: Gonadorelin — hpg axis support during/after trt; Histrelin (Supprelin LA / Vantas) — central precocious puberty (supprelin la).
- Tag: Hormonal · HPG axis vs FDA-Approved · Endocrine.